Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 14, 2013, Pages

  Gil, Margaret ^a   Seshadri, Mukund ^a   Komorowski, Marcin P ^a   Abrams, Scott I ^a   Kozbor, Danuta ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Vascular targeting; Viral oncotherapy

Indexed keywords

CANCER ANTIBODY; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANALYSIS OF VARIANCE; ANIMALS; BREAST NEOPLASMS; CHEMOKINE CXCL12; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES; ONCOLYTIC VIROTHERAPY; PEPTIDES; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; VACCINIA VIRUS;

MUS; VACCINIA VIRUS;

EID: 84875830856     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220580110     Document Type: Article

References (68)

1. Müller A, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50-56.
2. Kato M, Kitayama J, Kazama S, Nagawa H (2003) Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 5(5):R144-R150.
3. Kang H, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG (2005) The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 14(5): 360-367.
4. Salvucci O, et al. (2006) The role of CXCR4 receptor expression in breast cancer: A large tissue microarray study. Breast Cancer Res Treat 97(3):275-283.
5. Woo SU, Bae JW, Kim CH, Lee JB, Koo BW (2008) A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol 15(1):281-285.
6. Chu QD, et al. (2010) High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res 159(2):689-695.
7. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA (1996) A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184(3):1101-1109.
8. Burger JA, Kipps TJ (2006) CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5):1761-1767.
9. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA (2009) Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 4(11):e7965.
10. Orimo A, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3):335-348.
11. Teicher BA, Fricker SP (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16(11):2927-2931.
12. Scotton CJ, et al. (2002) Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62(20):5930-5938.
13. Orimo A, Weinberg RA (2006) Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 5(15):1597-1601.
14. Liu BY, et al. (2010) Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells. PLoS ONE 5(1):e8611.
15. Wald O, et al. (2006) CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol 177(10):6983-6990.
16. Devine SM, et al. (2004) Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non- Hodgkin's lymphoma. J Clin Oncol 22(6):1095-1102.
17. Wong D, Korz W (2008) Translating an antagonist of chemokine receptor CXCR4: From bench to bedside. Clin Cancer Res 14(24):7975-7980.
18. Gupta SK, Pillarisetti K (1999) Cutting edge: CXCR4-Lo: Molecular cloning and functional expression of a novel human CXCR4 splice variant. J Immunol 163(5): 2368-2372.
19. Broxmeyer HE, et al. (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201(8): 1307-1318.
20. Breitbach CJ, et al. (2011) Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477(7362):99-102.
21. Kirn DH, Thorne SH (2009) Targeted and armed oncolytic poxviruses: A novel multimechanistic therapeutic class for cancer. Nat Rev Cancer 9(1):64-71.
22. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL (1998) Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA 95(13): 7544-7549.
23. Vanderplasschen A, Hollinshead M, Smith GL (1997) Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol 78(Pt 8):2041-2048.
24. Yang Y, Huang CT, Huang X, Pardoll DM (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5(5):508-515.
25. Zhu J, Martinez J, Huang X, Yang Y (2007) Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109(2): 619-625.
26. Alcamí A, Symons JA, Smith GL (2000) The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 74(23):11230-11239.
27. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH (2007) Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 4(12):e353.
28. Hassan S, et al. (2011) CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 129(1):225-232.
29. Huang EH, et al. (2009) A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155(2):231-236.
30. Richert MM, et al. (2009) Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 21(3):761-767.
31. Bao L, et al. (2011) Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol 178(2):838-852.
32. Puhlmann M, et al. (2000) Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 7(1):66-73.
33. Breitbach CJ, et al. (2007) Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15(9):1686-1693.
34. Liu TC, Galanis E, Kirn D (2007) Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol 4(2):101-117.
35. Newman PJ, et al. (1990) PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 247(4947):1219-1222.
36. Albelda SM (1991) Endothelial and epithelial cell adhesion molecules. Am J Respir Cell Mol Biol 4(3):195-203.
37. Vanzulli S, et al. (1997) Detection of endothelial cells by MEC 13.3 monoclonal antibody in mice mammary tumors. Biocell 21(1):39-46.
38. Scholzen T, Gerdes J (2000) The Ki-67 protein: From the known and the unknown. J Cell Physiol 182(3):311-322.
39. Gil M, et al. (2011) Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice. Br J Cancer 105(10):1512-1521.
40. Liang Z, et al. (2007) CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 359(3):716-722.
41. Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9(Suppl 1):2-10.
42. Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25(4):581-611.
43. Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103(33):12493-12498.
44. Nathan C (2006) Neutrophils and immunity: Challenges and opportunities. Nat Rev Immunol 6(3):173-182.
45. Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI (2012) Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 91(1):167-181.
46. Breitbach CJ, et al. (2011) Targeting tumor vasculature with an oncolytic virus. Mol Ther 19(5):886-894.
47. Jack AM, Aydin N, Montenegro G, Alam K, Wallack M (2007) A novel dendritic cellbased cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model. J Surg Res 139(2):164-169.
48. Bolesta E, et al. (2005) DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res 65(8):3410-3418.
49. Wierzbicki A, et al. (2008) Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells. J Immunol 181(9): 6644-6653.
50. Gil M, et al. (2009) Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice. J Immunol 183(10):6808-6818.
51. Mastrangelo MJ, et al. (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6(5):409-422.
52. Shaked Y, Kerbel RS (2007) Antiangiogenic strategies on defense: On the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 67(15):7055-7058.
53. Yan HH, et al. (2010) Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res 70(15):6139-6149.
54. Liang Z, et al. (2005) Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65(3):967-971.
55. Smith MC, et al. (2004) CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64(23):8604-8612.
56. Ravetch JV (2002) A full complement of receptors in immune complex diseases. J Clin Invest 110(12):1759-1761.
57. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310(5753):1510-1512.
58. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275-290.
59. Nelissen JM, Peters IM, de Grooth BG, van Kooyk Y, Figdor CG (2000) Dynamic regulation of activated leukocyte cell adhesion molecule-mediated homotypic cell adhesion through the actin cytoskeleton. Mol Biol Cell 11(6):2057-2068.
60. van Kempen LC, et al. (2000) Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 156(3):769-774.
61. Ihnen M, et al. (2008) Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 112(3):419-427.
62. Prud'homme GJ, et al. (2010) Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS ONE 5(11):e13831.
63. Schneider-Gädicke A, Schwarz E (1986) Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J 5(9):2285-2292.
64. Jensen FC, Girardi AJ, Gilden RV, Koprowski H (1964) Infection of human and simian tissue cultures with Rous sarcoma virus. Proc Natl Acad Sci USA 52:53-59.
65. Buller RM, Chakrabarti S, Cooper JA, Twardzik DR, Moss B (1988) Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol 62(3):866-874.
66. McCart JA, et al. (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61(24): 8751-8757.
67. Chakrabarti S, Sisler JR, Moss B (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23(6):1094-1097.
68. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.